.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Breast cancer continues to impact global health significantly. Consequently, researchers are developing siRNA breast cancer therapy to improve clinical outcomes. This innovative approach uses small interfering RNA (siRNA) to silence specific genes involved in tumor initiation. Furthermore, these molecules inhibit cancer progression by selectively degrading messenger RNA (mRNA) before protein synthesis occurs.
Successful therapy depends heavily on effective delivery mechanisms. Since naked siRNA degrades rapidly in the bloodstream, scientists use sophisticated nanocarriers for protection. For instance, liposomes and metal nanoparticles facilitate cellular uptake and ensure stable transport. Moreover, carbon nanoparticles offer a versatile platform for site-specific targeting. This strategy significantly minimizes systemic side effects for the patient.
One promising aspect of this technology is its ability to mitigate drug resistance. By silencing genes responsible for drug efflux pumps, this therapy can sensitize resistant cells to chemotherapy. Additionally, combining siRNA with traditional treatments allows for a more personalized approach. Therefore, clinicians can target multiple oncogenic pathways simultaneously to prevent tumor recurrence effectively.
Despite the potential benefits, several obstacles remain in clinical translation. Researchers must overcome concerns regarding delivery efficiency and immune responses. Furthermore, suppressing off-target genes is essential to ensure patient safety. However, ongoing breakthroughs in biomimetic nanoparticles suggest that these hurdles are surmountable. These advancements represent a transformative shift toward targeted oncological care.
siRNA targets breast cancer cells by binding to specific messenger RNA sequences. This binding triggers the degradation of the mRNA. Consequently, this silences the expression of genes that drive tumor growth and survival.
The primary delivery vehicles include lipid-based nanoparticles, polymeric nanoparticles, and inorganic carriers like metal or carbon nanoparticles. These systems protect the siRNA from enzymatic degradation and enhance its uptake by tumor cells.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. The information provided should not be used for diagnosing or treating a health problem or disease. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This article reviews siRNA-based therapy for breast cancer, focusing on delivery mechanisms, gene suppression, and overcoming treatment resistance....
3 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
